{
  "_id": "2316528f41583d3887804fc8981781f32a51224c0ac8ace583f0914cb1c8f4bc",
  "feed": "market-watch",
  "title": "U.S. IPO market bracing for second-biggest deal of the year so far in eyecare health company Bausch + Lomb; Bausch + Lomb 'is highly profitable with strong cash flow, and it has global brand awareness of more than 70%,' says Renaissance Capital",
  "text": "<p>The biggest deal so far was that of private-equity firm TPG Inc. TPG, which raised $1 billion in January some 30 years after launching under the name Texas Pacific Group. That company was valued at $9 billion.</p><p>Also Read: The TPG IPO: 5 things to know about private-equity firm valued at $9 billion</p><p>The company is being spun out of healthcare company Bausch Health Inc. BHC and will list on the New York Stock Exchange and TSX under the ticker \"BLCO.\"</p><p>\" While it faces significant competition from other brands and generic products, the company is highly profitable with strong cash flow, and it has global brand awareness of more than 70%,\" said Renaissance Capital, a provider of IPO exchange-traded funds and institutional research in commentary.</p><p>Morgan Stanley and Goldman Sachs are the lead underwriters in a syndicate of 20 banks working on the deal. Proceeds will all go to the selling shareholder, a wholly owned unit of Bausch Health, according to the filing documents.</p><p>See also: Piano maker Steinway is going public again: 5 things to know ahead of its IPO</p><p>The company BLCO had a net profit of $182 million in 2021 on revenue of $3.765 billion. That compares with the loss of $18 million on revenue of $3.412 billion generated in 2020.</p><p>Bausch + Lomb was founded in 1853 by John Jacob Bausch and Henry Lomb, and started as a small optical goods shop in Rochester, New York.</p><p>\"Our mission is simple, yet powerful: helping you see better, to live better,\" says the prospectus summary.</p><p>Bausch &amp; Lomb makes contact lenses, intraocular lenses, medical devices, surgical systems, vitamin and mineral supplements, lens care products, prescription eye-medications and over-the-counter eye health consumer products.</p><p>It has about 4,200 employees at 24 facilities in 10 countries. Its research &amp; development team number about 850 and they have introduced more than 260 new products since 2017.</p><p>See: IPO market outlook is 'foggy' heading into second quarter as falling returns at year-end and war in Europe dampens risk appetite</p><p>The company developed the world's first soft contact lens, it launched one of the first contact lens cleaning products, introduced the first silicon hydrogel contact lens and brought a patented ocular vitamin to market, according to the prospectus.</p><p>The global eyecare market was worth nearly $50 billion in revenue in 2019, it said, and Bausch + Lomb is expecting it to grow at a compound annual growth rate of nearly 4% through 2025 to $63.2 billion.</p><p>That growth will be driven by factors including an aging global population, the rapid growth of a middle class in emerging markets, the increasing prevalence of diabetes and improving access to medical practitioners, among others.</p><p>The company is one of two that Bausch Health is spinning off as it works to reduce a massive debt burden taken on when it was called Valeant and went on a huge acquisition spree. The second is Solta Medical, which is Bausch's skin care business.</p><p>Bausch Health has about $22.7 billion in long-term debt, according to FactSet.</p><p>Rounding out this week's IPO calendar are two other deals, that of biotech PepGen and Austin Gold, according to Renaissance Capital.</p><p>PepGen PEPG, which is developing products aimed at treating neuromuscular and neurological diseases, is seeking to raise up to $108 million to fund clinical trials and develop its pipeline.</p><p>Austin Gold is a miner with properties in Nevada that is seeking to raise $13 million to fund exploration activities.</p><p>A handful of special-purpose acquisition corporations, or SPACs, may also price, according to Renaissance Capital, after joining the calendar let.</p><p>\"Blank check issuance has been on a steady decline since the start of the year driven by poor post-merger returns, which have incited a wave of merger terminations and SPAC IPO withdrawals,\" said the commentary.</p><p>The Renaissance IPO ETF IPO is down 39% in the year to date, while the S&amp;P 500 IPO has lost 14%.</p><p>U.S. IPO market bracing for second-biggest deal of the year so far in eyecare health company Bausch + Lomb</p>",
  "published": "2022-05-02T18:25:00.000Z",
  "tags": [
    {
      "id": "US38141G1040",
      "nexusId": "10038135",
      "name": "The Goldman Sachs Group, Inc.",
      "offsets": [
        {
          "start": 768,
          "end": 781
        },
        {
          "start": 768,
          "end": 775
        }
      ]
    }
  ]
}